^
    Back
    Association details:
    Biomarker:EGFR exon 21 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    Published date:
    03/17/2022
    Excerpt:
    In the whole cohort, the median PFS was 17.5 months (mo.) (95% CI, 13.2-24.9) and median OS 47 mo (95%CI, 47-not reached [NR])...when analysed separately: the median PFS was NR (11.3-NR) in the KRASm G12C vs. 8.1 mo (5.8-NR) in the EGFRm del19/ex21 vs. 7.8 mo (7.7-NR) in the BRAFm V600E/ALKr (P = 0.02)....We observed limited activity of durvalumab consolidation in patients with stage III unresectable NSCLC with EGFR/BRAFm and ALKr but not for those harbouring KRASm.
    DOI:
    10.1016/j.ejca.2022.02.014